Gilead monopoly blocks cryptococcal meningitis treatment for people living with HIV
Cryptococcal Disease and Treatment Access: Frequently asked questions and key messages to Gilead
Category: Our Impact
-
-
Community Resource for Access to COVID-19 Medical Technology
Activists have a prime opportunity to prevent pharmaceutical corporations and others from additional profiteering at the expense of global public health—and people’s lives.
-
PLHIV Communities are central to future integrated systems for health
The past three decades have demonstrated that communities of PLHIV are central to effective advocacy for health equity, and ensuring that the human rights of all people are recognized and upheld.
-
ITPC at IAS 2021: How COVID-19 changed HIV Treatment
The impact of differentiated service delivery during the COVID-19 pandemic is one of the central themes of this year’s International AIDS Society Conference on HIV...
-
COVID-19 timeline: free, fact-checking & research tool for journalists, academics, treatment activists & others
Make Medicines Affordable launched the COVID-19 timeline as a free, fact-checking and research tool for journalists, academics, treatment activists and others.
-
Monopolies causing “artificial rationing” in COVID-19 crisis as 3 biggest global vaccine giants sit on sidelines
The supply of safe and effective vaccines for all is being artificially rationed because of the protection of exclusive rights and monopolies of pharmaceutical corporations.
-
HIV activists are essential to the COVID-19 response
Groundbreaking research has saved millions of lives, but the decisions taken by executives have ended millions of others. Countries should act now, and not to rely on the actions of pharma.
-
Who will get Pfizer’s COVID-19 vaccine?
A vaccine must reach the most vulnerable in each and every country and around the same time. Who gets the vaccine first must be based on need – not purchasing power. We demand affordable prices and fair allocation.
-
Ukraine’s reformed patent law comes into effect due to advocacy work
Dolutegravir (DTG) is widely available in Ukraine due to advocacy work. It provides a framework to prevent unlawful patents and monopolies on essential drugs, which have restricted access to life-saving treatment in the country.
-
NEW DATA: Treat 95% of people living with HIV for just FOUR WEEKS of global HIV drug sales.
The Make Medicines Affordable campaign is calling for a widespread switch from patented to generic HIV drugs so that at...
-
Frontline activism for health and human rights among women living with HIV and using drugs in the era of COVID-19 in Nepal
In 2006, Parina Subba founded an organisation named Dristi (meaning ‘vision’ in Nepali). Dristi’s motto is, simply: ‘Rights to existence’....
-
How Far Would YOU Go?
COVID-19 pushed these men to extremes to protect their own.
